hydralazine has been researched along with Chronic Kidney Diseases in 15 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We present a case report of a premenopausal patient with hydralazine-associated amenorrhea." | 8.98 | Hydralazine-associated Amenorrhea in a Premenopausal Patient With Chronic Kidney Disease: A Case Report and Review of Literature. ( Al-Makki, A; Allspaw, A; Shepler, BM; Yeboah, KA, 2018) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 8.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 5.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| " We present a case report of a premenopausal patient with hydralazine-associated amenorrhea." | 4.98 | Hydralazine-associated Amenorrhea in a Premenopausal Patient With Chronic Kidney Disease: A Case Report and Review of Literature. ( Al-Makki, A; Allspaw, A; Shepler, BM; Yeboah, KA, 2018) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 4.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| " Among blacks with hypertensive chronic kidney disease, neither PM (bedtime) dosing of once-daily antihypertensive nor the addition of drugs taken at bedtime significantly reduced nocturnal BP compared with morning dosing of antihypertensive medications." | 2.78 | A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. ( Agodoa, LY; Appel, LJ; Bakris, GL; Charleston, J; Contreras, G; Gabbai, F; Greene, T; Hiremath, L; Jamerson, K; Kendrick, C; Kusek, JW; Lash, JP; Lea, J; Miller, ER; Phillips, RA; Rahman, M; Rostand, S; Toto, R; Wang, X; Wright, JT, 2013) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 1.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| "Renal fibrosis was increased 2." | 1.42 | A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression. ( Bin, W; Cao, W; Hou, FF; Li, A; Su, Z; Wang, L; Wilcox, CS; Zhou, Z, 2015) |
| "Treatment with hydralazine at hypotensive dose for 12 weeks also failed to affect the proteinuria in 5 of 6 nephrectomized CKD rats." | 1.40 | Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats. ( Ayajiki, K; Funai, A; Kobuchi, S; Matsumura, Y; Ohkita, M; Suzuki, R; Tanaka, R; Tsutsui, H; Yazawa, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Larkin, BP | 1 |
| Nguyen, LT | 1 |
| Hou, M | 1 |
| Glastras, SJ | 1 |
| Chen, H | 1 |
| Faiz, A | 1 |
| Chen, J | 1 |
| Wang, R | 1 |
| Pollock, CA | 1 |
| Saad, S | 1 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Fang, SY | 1 |
| Lin, SC | 1 |
| Chen, JW | 2 |
| Chang, TT | 2 |
| Hayashi, K | 1 |
| Shimokawa, T | 1 |
| Yamagata, M | 1 |
| Yoneda, K | 1 |
| Fujita, Y | 1 |
| Ichikawa, D | 1 |
| Sugaya, T | 1 |
| Ohata, K | 1 |
| Tanabe, J | 1 |
| Inoue, K | 1 |
| Hoshino, S | 1 |
| Togo, T | 1 |
| Watanabe, M | 1 |
| Kimura, K | 1 |
| Shibagaki, Y | 1 |
| Kamijo-Ikemori, A | 1 |
| Yeboah, KA | 1 |
| Allspaw, A | 1 |
| Al-Makki, A | 1 |
| Shepler, BM | 1 |
| Sogawa, Y | 1 |
| Nagasu, H | 1 |
| Itano, S | 1 |
| Kidokoro, K | 1 |
| Taniguchi, S | 1 |
| Takahashi, M | 1 |
| Kadoya, H | 1 |
| Satoh, M | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Kobuchi, S | 1 |
| Tanaka, R | 1 |
| Funai, A | 1 |
| Suzuki, R | 1 |
| Yazawa, M | 1 |
| Tsutsui, H | 1 |
| Ohkita, M | 1 |
| Ayajiki, K | 1 |
| Matsumura, Y | 1 |
| Cao, W | 1 |
| Li, A | 1 |
| Wang, L | 1 |
| Zhou, Z | 1 |
| Su, Z | 1 |
| Bin, W | 1 |
| Wilcox, CS | 1 |
| Hou, FF | 1 |
| Ueda, M | 1 |
| Uchimura, K | 1 |
| Narita, Y | 1 |
| Miyasato, Y | 1 |
| Mizumoto, T | 1 |
| Morinaga, J | 1 |
| Hayata, M | 1 |
| Kakizoe, Y | 1 |
| Adachi, M | 1 |
| Miyoshi, T | 1 |
| Shiraishi, N | 1 |
| Kadowaki, D | 1 |
| Sakai, Y | 1 |
| Mukoyama, M | 1 |
| Kitamura, K | 1 |
| Yee, J | 1 |
| Tampe, B | 1 |
| Steinle, U | 1 |
| Tampe, D | 1 |
| Carstens, JL | 1 |
| Korsten, P | 1 |
| Zeisberg, EM | 1 |
| Müller, GA | 1 |
| Kalluri, R | 1 |
| Zeisberg, M | 1 |
| Nishihara, M | 1 |
| Takesue, K | 1 |
| Hirooka, Y | 1 |
| Rahman, M | 1 |
| Greene, T | 1 |
| Phillips, RA | 1 |
| Agodoa, LY | 1 |
| Bakris, GL | 1 |
| Charleston, J | 1 |
| Contreras, G | 1 |
| Gabbai, F | 1 |
| Hiremath, L | 1 |
| Jamerson, K | 1 |
| Kendrick, C | 1 |
| Kusek, JW | 1 |
| Lash, JP | 1 |
| Lea, J | 1 |
| Miller, ER | 1 |
| Rostand, S | 1 |
| Toto, R | 1 |
| Wang, X | 1 |
| Wright, JT | 1 |
| Appel, LJ | 1 |
| LICHTIG-DINULESCU, E | 1 |
| BOROS, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| African American Study of Kidney Disease and Hypertension ABPM Pilot Study[NCT00582777] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Effect of Potassium Losartan With Bedtime Dosing on Chronic Kidney Disease Patients With Nondipping Blood Pressure Pattern[NCT03603938] | 189 participants (Anticipated) | Interventional | 2018-11-01 | Not yet recruiting | |||
| Prognostic Effect of Isolated Nocturnal Hypertension Pattern With Nondialysis CKD[NCT03604003] | 252 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydralazine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Hydralazine-associated Amenorrhea in a Premenopausal Patient With Chronic Kidney Disease: A Case Report and Review of Literature.
Topics: Adult; Amenorrhea; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension; Premenopause; | 2018 |
1 trial available for hydralazine and Chronic Kidney Diseases
| Article | Year |
|---|---|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2013 |
13 other studies available for hydralazine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K | 2022 |
Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Enzyme Inhibitors; Fibrosis; Humans; Hydralazine; Inflammation; Kidney | 2023 |
Hydralazine improves ischemia-induced neovasculogenesis via xanthine-oxidase inhibition in chronic renal insufficiency.
Topics: Allopurinol; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Enzyme Inhibitors; H | 2020 |
Inhibition of α
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blister; Disease Models, Animal; Disease Progressi | 2021 |
Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion.
Topics: Angiotensin II; Animals; Blood Pressure; Hydralazine; Ischemia; Kidney; Male; Mice; Mice, Knockout; | 2021 |
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice.
Topics: Aldosterone; Animals; Antihypertensive Agents; Disease Models, Animal; Endothelium; Fibrosis; Humans | 2018 |
Involvement of renal sympathetic nerve overactivation in the progression of chronic kidney disease in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Autonom | 2014 |
A Salt-Induced Reno-Cerebral Reflex Activates Renin-Angiotensin Systems and Promotes CKD Progression.
Topics: Analysis of Variance; Animals; Blotting, Western; Brain; Disease Models, Animal; Disease Progression | 2015 |
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Blood Pressure; Creatinine; Disease Progression; Est | 2015 |
PGX: Pharmacogenomics During Generation X.
Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; H | 2016 |
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Animals; CpG Islands; Dioxygenases; D | 2017 |
Renal denervation enhances GABA-ergic input into the PVN leading to blood pressure lowering in chronic kidney disease.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Denervation; Disease Models, Animal; Eating; GABAe | 2017 |
[Acute renal insufficiency during hydrazinophthalazine therapy of chronic renal insufficiency].
Topics: Acute Kidney Injury; Humans; Hydralazine; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 1957 |